Page last updated: 2024-12-05

indoprofen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Indoprofen is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. It is used to treat pain and inflammation associated with various conditions, including rheumatoid arthritis, osteoarthritis, and gout. Indoprofen is a propionic acid derivative and is synthesized through a multi-step process involving the reaction of an aromatic amine with propionic acid. The drug exerts its therapeutic effects by inhibiting the production of prostaglandins, which are inflammatory mediators. Indoprofen is studied extensively for its potential to manage pain, reduce inflammation, and improve quality of life in patients with chronic inflammatory conditions. Its efficacy and safety profile have been established in numerous clinical trials. Furthermore, ongoing research explores its potential applications in other inflammatory diseases, such as inflammatory bowel disease and cancer. '

Indoprofen: A drug that has analgesic and anti-inflammatory properties. Following reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p21) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

indoprofen : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(1-oxo-1,3-dihydroisoindol-2-yl)phenyl group. Initially used as an anti-inflammatory and analgesic, it was withdrawn from the market due to causing severe gastrointestinal bleeding. It has been subsequently found to increase production of the survival motor neuron protein. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3718
CHEMBL ID15870
CHEBI ID76162
SCHEMBL ID25137
MeSH IDM0011252

Synonyms (140)

Synonym
MLS001146951
BRD-A44090213-001-05-8
KBIO1_000401
DIVK1C_000401
MLS000069761 ,
smr000058710
alpha-methyl-p-[1-oxo-2-isoindolinyl]-benzeneacetic acid
SPECTRUM_000941
PRESTWICK2_000836
SPECTRUM5_000870
indoprofenum [inn-latin]
4-(1-oxo-2-isoindolinyl)hydratropasaeure
hydratropic acid, p-(1-oxo-2-isoindolinyl)-
4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-alpha-methylbenzeneacetic acid
2-(4-(1-carboxyethyl)phenyl)-1-isoindolinone
indoprofeno [inn-spanish]
2-(4-(1-oxo-2-isoindolinyl)phenyl)propionsaeure
alpha-(4-(1-oxo-2-iso-indolinyl)-phenyl)-propionic acid
benzeneacetic acid, 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-alpha-methyl-
p-(1-oxo-2-isoindolinyl)hydratropic acid
1-oxo-2-(p-((alpha-methyl)carboxymethyl)phenyl)isoindoline
indoprofene [inn-french]
propionic acid, alpha-(4-(1-oxo-2-isoindolinyl)phenyl)-
propionic acid, 2-(p-(1-oxo-2-isoindolinyl)phenyl)-
einecs 250-833-0
PRESTWICK_1001
cas-31842-01-0
BSPBIO_002178
indoprofen
isindone
flosint
flosin
reumofene
4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-.alpha.-methylbenzeneacetic acid
2-[4-(1-oxoisoindolin-2-yl)phenyl]propanoic acid
31842-01-0
k 4277
D04530
indoprofen (usan/inn)
BSPBIO_000791
PRESTWICK3_000836
MLS001333196
MLS001333195
k-4277 ,
AB00052023
BPBIO1_000871
NCGC00094700-01
NCGC00094700-02
KBIOSS_001421
KBIO3_001398
KBIO2_001421
KBIOGR_000397
KBIO2_006557
KBIO2_003989
SPECTRUM2_000785
PRESTWICK1_000836
SPBIO_002712
SPECTRUM3_000469
PRESTWICK0_000836
SPBIO_000890
SPECTRUM4_000019
NINDS_000401
SPECTRUM1500351
IDI1_000401
NCGC00094700-04
NCGC00094700-03
HMS2091N11
VU0243102-4
nsc-757065
praxis
bor-ind
chebi:76162 ,
CHEMBL15870 ,
HMS501E03
2-[4-(1-oxo-1,3-dihydro-isoindol-2-yl)-phenyl]-propionic acid
(+)-2-(4-(1-oxoisoindolin-2-yl)phenyl)propanoic acid
bdbm50233673
cid_3718
2-(4-(1-oxoisoindolin-2-yl)phenyl)propanoic acid
HMS1920H03
HMS1570H13
2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid
HMS2097H13
pharmakon1600-01500351
nsc757065
tox21_111316
dtxcid3025831
dtxsid5045831 ,
2-[4-(1-oxo-1,3-dihydro-2h-isoindol-2-yl)phenyl]propanoic acid
HMS2230L16
CCG-40163
cpe46zu14n ,
indoprofenum
indoprofeno
nsc 757065
(+-)-4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-alpha-methylbenzeneacetic acid
indoprofene
indoprofen [usan:inn:ban]
unii-cpe46zu14n
benzeneacetic acid, 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-alpha-methyl-, (+-)-
FT-0630559
AKOS015900986
S2272
SCHEMBL25137
alpha-(4-(1-oxo-2-isoindolinyl)phenyl)propionic acid
indoprofen [mi]
1-oxo-2-(p-((.alpha.-methyl)carboxymethyl)phenyl)isoindoline
benzeneacetic acid, 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-.alpha.-methyl-
2-(4-(1-oxo-2-isoindolinyl)phenyl)propionic acid
indoprofen [who-dd]
indoprofen [inn]
53022-60-9
indoprofen [mart.]
indoprofen [usan]
CS-4695
RJMIEHBSYVWVIN-UHFFFAOYSA-N
alpha-[p-(1-oxo-2-isoindolinyl)phenyl]propionic acid
2-[4-(1-oxo-2-isoindolinyl)phenyl]propionic acid
alpha-[p-(1-oxo-2-isoindolinyl) phenyl]propionic acid
HY-B1104
AB00052023_15
OPERA_ID_630
alpha-methyl-p-(1-oxo-2-isoindolinyl)benzeneacetic acid
mfcd00057144
DB08951
( inverted exclamation marka)-indoprofe
SR-01000712384-3
sr-01000712384
SR-01000712384-2
2-[4-(1-oxo-2,3-dihydro-1h-isoindol-2-yl)phenyl]propanoic acid
indoprofen, analytical standard
SBI-0051416.P003
indoprofen o
HMS3714H13
Q3798358
BS-16916
BRD-A44090213-001-15-7
(+/-)-indoprofe
D81783
()-indoprofe

Research Excerpts

Overview

Indoprofen is a non-steroidal anti-inflammatory drug. It has provided insights into treatment of spinal muscular atrophies. The treatment effect on sepsis and the underlying mechanism remain to be elucidated.

ExcerptReferenceRelevance
"Indoprofen is a non-steroidal anti-inflammatory drug, and has provided insights into treatment of spinal muscular atrophies; however, the treatment effect of indoprofen on sepsis and the precise underlying mechanism remain to be elucidated. "( Indoprofen exerts a potent therapeutic effect against sepsis by alleviating high mobility group box 1-mediated inflammatory responses.
Bi, X; Jiang, B; Liang, J; Liu, J; Lu, S; Luo, L; Yan, X; Yin, Z; Zhou, J, 2021
)
3.51
"Indoprofen is an isoindoline derivative of phenylpropionic acid. "( Preclinical studies on indoprofen, a new non-steroidal analgesic-antiinflammatory agent.
Buttinoni, A; Tommasini, R, 1981
)
2.02
"Indoprofen seems to be a useful alternative, with low risk of central nervous side effects."( Comparison of a narcotic (oxicone) and a non-narcotic anti-inflammatory analgesic (indoprofen) in the treatment of renal colic.
Bergqvist, D; Melander, A; Persson, NH; Zederfelt, B, 1985
)
1.22

Effects

ExcerptReferenceRelevance
"Indoprofen has been studied in vitro as a possible selective inhibitor of thromboxane-synthetase in guinea pig lungs perfused with arachidonic acid. "( Effect of indoprofen on prostaglandin and thromboxane A2 synthesis in the guinea pig lung.
Ceserani, R; Colombo, M; Mandelli, V, 1979
)
2.1

Treatment

ExcerptReferenceRelevance
"Each treatment (indoprofen 300 or 600 mg/day, ASA 1500 + diazepam 6 mg/day, and matching placebo) was administered for 7 days."( Double-blind cross-over investigation of the effectiveness and safety of two doses of indoprofen compared with an ASA preparation and placebo in patients suffering from osteoarthritis.
Bergamini, N; Groppi, W; Mandelli, V; Valtonen, E, 1981
)
0.82

Toxicity

ExcerptReferenceRelevance
" The incidence of adverse events during each period did not seem to depend either on the treatment being given during that period or on the previous one."( Double-blind cross-over investigation of the effectiveness and safety of two doses of indoprofen compared with an ASA preparation and placebo in patients suffering from osteoarthritis.
Bergamini, N; Groppi, W; Mandelli, V; Valtonen, E, 1981
)
0.49

Pharmacokinetics

The half-life of indoprofen in plasma is approximately 7 h for males and 16 h for females. As it has been shown that its pharmacological effects are almost entirely due to the (+) isomer, some pharmacokinetic properties of the latter have been studied in man.

ExcerptReferenceRelevance
" As it has been shown that its pharmacological effects are almost entirely due to the (+) isomer (d-indoprofen), some pharmacokinetic properties of the latter have been studied in man in comparison with the racemic mixture given by oral administration, d-indoprofen is cleared from plasma and excreted in urine (as unchanged plus conjugated drug) at a slower rate than l-indoprofen."( Pharmacokinetics of the enantiomers of indoprofen in man.
Groppi, W; Jannuzzo, MG; Moro, E; Nicolis, FB; Stegnjaich, S; Tamassia, V, 1984
)
0.75
" The half-life of indoprofen in plasma is approximately 7 h for males and 16 h for females."( Pharmacokinetics and metabolism of indoprofen in the hamster.
Goldaniga, GC; Montesanti, L; Moro, E; Pianezzola, E; Valzelli, G, 1980
)
0.87

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of indoprofen tablets is not adversely affected by the presence of food in the gastrointestinal tract."( Human pharmacokinetics of indoprofen.
Tamassia, V, 1981
)
0.87
"To estimate the bioavailability and evaluate bioequivalence of a single dose of a dexibuprofen tablet (test formulation, containing dexibuprofen 400 mg, manufactured by Emcure Pharmaceuticals Ltd."( A randomized, crossover study to determine bioequivalence of two brands of dexibuprofen 400 mg tablets in healthy Asian adult male subjects of Indian origin.
Kadam, N; Menon, S; Mhatre, P; Patil, G, 2008
)
0.35
" When the AUC0-t values for both formulations for non-transformed and log-transformed data were compared, the test formulation showed a bioavailability of 98."( A randomized, crossover study to determine bioequivalence of two brands of dexibuprofen 400 mg tablets in healthy Asian adult male subjects of Indian origin.
Kadam, N; Menon, S; Mhatre, P; Patil, G, 2008
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Multiple dosing four times daily for 7 days of indoprofen 200 mg, a non-steroidal anti-inflammatory drug with a short half-life (t1/2), revealed drug accumulation in eight elderly subjects. The initial steroid dosage could be reduced 72% in the indoprafen group and 53% inthe indomethacin group. 50% of the patients receiving indoprfen and 22.5% of those receiving ASA were treated for renal colic.

ExcerptRelevanceReference
" A double-placebo method was used, as dosage regimens for the two treatments were different."( The effects of indoprofen vs paracetamol on swelling, pain and other events after surgery.
Olstad, OA; Skjelbred, P, 1986
)
0.62
"Multiple dosing four times daily for 7 days of indoprofen 200 mg, a non-steroidal anti-inflammatory drug with a short half-life (t1/2), revealed drug accumulation in eight elderly subjects."( Pharmacokinetic profile of indoprofen in elderly subjects.
Andersen, RB; Egsmose, C; Knudsen, O; Lund, B, 1986
)
0.83
" During the dosage interval indoprofen levels were appreciably higher in elderly patients than in healthy volunteers due to higher nadir values and slower elimination half-lives, whereas only minor differences could be detected for peak plasma levels."( Pharmacokinetics of indoprofen in elderly patients following repeated oral administration.
Kurowski, M, 1985
)
0.89
" A dose-response study has therefore been performed in patients with renal colic, using two intravenous non-steroidal antiinflammatory drugs, indoprofen and lysine acetylsalicylate (ASA)."( Intravenous indoprofen in the management of renal colic.
Bruni, G; Lavezzari, M; Mandelli, V; Torchi, B; Villani, U, 1983
)
0.85
" Pharmacokinetics are no substitute for clinical experiment in planning the dosage regime of a non-steroidal anti-inflammatory drug."( How frequently should anti-inflammatory drugs be given? A study with indoprofen.
Christophidis, N; Huskisson, EC; Scott, J, 1981
)
0.5
" Each patient received IP 600 mg/day or ASA 2100 mg/day for a four-week period; after a one-week wash-out period, the same drug was given at a higher dosage (IP 800 or ASA 2800 mg/day) for another four weeks."( Double-blind comparative trial of indoprofen and acetylsalicylic acid in osteoarthritis.
Katona, G, 1981
)
0.54
" The initial steroid dosage could be reduced 72% in the indoprofen group and 53% in the indomethacin group; 50% of the patients receiving indoprofen and 22."( Double-blind multicentre, between patients comparison of indoprofen and indomethacin in rheumatoid arthritis patients under basic steroid treatment.
del Campo, JB, 1981
)
0.75
" In all subjects the dosage of W was kept constant throughout the study (21 days)."( Clinical study of possible interactions between indoprofen and oral anticoagulants.
Bergamini, N; Bianchi, A; Caso, P; Gualtieri, S; Iadevaia, V; Jacono, A; Raucci, D; Vigorito, C, 1981
)
0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitorA compound or agent that combines with cyclooxygenases (EC 1.14.99.1) and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of icosanoids, prostaglandins, and thromboxanes.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
isoindoles
gamma-lactamA lactam in which the amide bond is contained within a five-membered ring, which includes the amide nitrogen and the carbonyl carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (71)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency0.22480.007215.758889.3584AID588342; AID624030
glp-1 receptor, partialHomo sapiens (human)Potency6.30960.01846.806014.1254AID624417
ATAD5 protein, partialHomo sapiens (human)Potency0.41090.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency21.73020.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency5.60750.000221.22318,912.5098AID743036; AID743042; AID743053; AID743054
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.95210.000214.376460.0339AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency9.61860.000229.305416,493.5996AID743075; AID743079; AID743080; AID743091
67.9K proteinVaccinia virusPotency5.01190.00018.4406100.0000AID720580
luciferasePhoturis pensylvanica (Pennsylania firefly)Potency14.12540.891310.432820.5750AID1379
P53Homo sapiens (human)Potency10.00000.07319.685831.6228AID504706
pyruvate kinaseLeishmania mexicana mexicanaPotency15.84890.398113.744731.6228AID1721; AID1722
IDH1Homo sapiens (human)Potency1.63600.005210.865235.4813AID686970
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency3.54810.016525.307841.3999AID602332
aryl hydrocarbon receptorHomo sapiens (human)Potency0.05960.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency21.13170.001723.839378.1014AID743083
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency0.10000.10009.191631.6228AID1346983
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency0.17780.036619.637650.1187AID1466; AID2242
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency0.08910.01262.451825.0177AID485313
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency10.00000.316212.443531.6228AID902; AID924
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency32.64270.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency1.36333.548119.542744.6684AID743266
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency7.64450.000323.4451159.6830AID743065; AID743067
huntingtin isoform 2Homo sapiens (human)Potency2.11700.000618.41981,122.0200AID2669; AID2673
importin subunit beta-1 isoform 1Homo sapiens (human)Potency20.59625.804836.130665.1308AID540253
ras-related protein Rab-9AHomo sapiens (human)Potency0.31620.00022.621531.4954AID485297
snurportin-1Homo sapiens (human)Potency20.59625.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency20.59625.804816.996225.9290AID540253
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency4.46680.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency4.46680.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency4.46680.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency4.92100.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency0.13580.004611.374133.4983AID624296; AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency3.78420.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency39.81070.031610.279239.8107AID884; AID885
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency7.94330.00419.962528.1838AID2675
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Integrin beta-3Homo sapiens (human)Potency10.00000.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency10.00000.316211.415731.6228AID924
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.17783.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.17783.548118.039535.4813AID1466
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Endothelin receptor type BRattus norvegicus (Norway rat)Potency15.84890.562315.160931.6228AID1721
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Endothelin-1 receptorRattus norvegicus (Norway rat)Potency15.84890.562315.160931.6228AID1721
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency0.59560.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency0.59560.011912.222168.7989AID651632
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty acid-binding protein, liverRattus norvegicus (Norway rat)Ki81.13500.01501.24876.9200AID407366; AID407369
Pyruvate kinase PKMHomo sapiens (human)IC50 (µMol)21.00000.50002.788610.0000AID1881891
Caspase-1Homo sapiens (human)IC50 (µMol)1.29200.00201.70138.8000AID1802657
Caspase-3Homo sapiens (human)IC50 (µMol)1.29200.00021.19798.8000AID1802657
Caspase-4Homo sapiens (human)IC50 (µMol)1.29200.30002.26418.8000AID1802657
Caspase-5Homo sapiens (human)IC50 (µMol)1.29200.30002.23588.8000AID1802657
Caspase-9Homo sapiens (human)IC50 (µMol)1.29200.30002.26418.8000AID1802657
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear factor NF-kappa-B p105 subunit isoform 1Homo sapiens (human)EC50 (µMol)1.51800.05905.559627.2100AID1241
transcription factor p65 isoform 1Homo sapiens (human)EC50 (µMol)1.51800.05905.559627.2100AID1241
Estrogen receptor betaMus musculus (house mouse)EC50 (µMol)1.51800.05905.559627.2100AID1241
Estrogen receptorMus musculus (house mouse)EC50 (µMol)1.51800.05905.559627.2100AID1241
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Survival motor neuron proteinHomo sapiens (human)Activity1.00001.22001.22001.2200AID616344
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (191)

Processvia Protein(s)Taxonomy
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
programmed cell deathPyruvate kinase PKMHomo sapiens (human)
canonical glycolysisPyruvate kinase PKMHomo sapiens (human)
positive regulation of sprouting angiogenesisPyruvate kinase PKMHomo sapiens (human)
positive regulation of cytoplasmic translationPyruvate kinase PKMHomo sapiens (human)
glycolytic processPyruvate kinase PKMHomo sapiens (human)
cellular response to insulin stimulusPyruvate kinase PKMHomo sapiens (human)
cellular response to organic substanceCaspase-1Homo sapiens (human)
pattern recognition receptor signaling pathwayCaspase-1Homo sapiens (human)
proteolysisCaspase-1Homo sapiens (human)
apoptotic processCaspase-1Homo sapiens (human)
signal transductionCaspase-1Homo sapiens (human)
osmosensory signaling pathwayCaspase-1Homo sapiens (human)
protein autoprocessingCaspase-1Homo sapiens (human)
positive regulation of interleukin-1 beta productionCaspase-1Homo sapiens (human)
positive regulation of interleukin-18 productionCaspase-1Homo sapiens (human)
defense response to bacteriumCaspase-1Homo sapiens (human)
regulation of apoptotic processCaspase-1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionCaspase-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processCaspase-1Homo sapiens (human)
icosanoid biosynthetic processCaspase-1Homo sapiens (human)
regulation of inflammatory responseCaspase-1Homo sapiens (human)
positive regulation of inflammatory responseCaspase-1Homo sapiens (human)
protein maturationCaspase-1Homo sapiens (human)
defense response to virusCaspase-1Homo sapiens (human)
pyroptosisCaspase-1Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-1Homo sapiens (human)
cellular response to mechanical stimulusCaspase-1Homo sapiens (human)
cellular response to type II interferonCaspase-1Homo sapiens (human)
cytokine precursor processingCaspase-1Homo sapiens (human)
signaling receptor ligand precursor processingCaspase-1Homo sapiens (human)
AIM2 inflammasome complex assemblyCaspase-1Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayCaspase-1Homo sapiens (human)
neurotrophin TRK receptor signaling pathwayCaspase-3Homo sapiens (human)
luteolysisCaspase-3Homo sapiens (human)
response to hypoxiaCaspase-3Homo sapiens (human)
B cell homeostasisCaspase-3Homo sapiens (human)
negative regulation of cytokine productionCaspase-3Homo sapiens (human)
proteolysisCaspase-3Homo sapiens (human)
apoptotic processCaspase-3Homo sapiens (human)
DNA damage responseCaspase-3Homo sapiens (human)
axonal fasciculationCaspase-3Homo sapiens (human)
heart developmentCaspase-3Homo sapiens (human)
sensory perception of soundCaspase-3Homo sapiens (human)
learning or memoryCaspase-3Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to osmotic stressCaspase-3Homo sapiens (human)
response to xenobiotic stimulusCaspase-3Homo sapiens (human)
response to UVCaspase-3Homo sapiens (human)
response to woundingCaspase-3Homo sapiens (human)
response to glucoseCaspase-3Homo sapiens (human)
response to X-rayCaspase-3Homo sapiens (human)
regulation of macroautophagyCaspase-3Homo sapiens (human)
protein processingCaspase-3Homo sapiens (human)
hippocampus developmentCaspase-3Homo sapiens (human)
protein catabolic processCaspase-3Homo sapiens (human)
erythrocyte differentiationCaspase-3Homo sapiens (human)
platelet formationCaspase-3Homo sapiens (human)
negative regulation of B cell proliferationCaspase-3Homo sapiens (human)
regulation of protein stabilityCaspase-3Homo sapiens (human)
response to cobalt ionCaspase-3Homo sapiens (human)
response to estradiolCaspase-3Homo sapiens (human)
response to lipopolysaccharideCaspase-3Homo sapiens (human)
glial cell apoptotic processCaspase-3Homo sapiens (human)
response to tumor necrosis factorCaspase-3Homo sapiens (human)
response to nicotineCaspase-3Homo sapiens (human)
response to hydrogen peroxideCaspase-3Homo sapiens (human)
T cell homeostasisCaspase-3Homo sapiens (human)
response to amino acidCaspase-3Homo sapiens (human)
fibroblast apoptotic processCaspase-3Homo sapiens (human)
cell fate commitmentCaspase-3Homo sapiens (human)
negative regulation of cell cycleCaspase-3Homo sapiens (human)
negative regulation of activated T cell proliferationCaspase-3Homo sapiens (human)
striated muscle cell differentiationCaspase-3Homo sapiens (human)
response to glucocorticoidCaspase-3Homo sapiens (human)
neuron apoptotic processCaspase-3Homo sapiens (human)
protein maturationCaspase-3Homo sapiens (human)
anterior neural tube closureCaspase-3Homo sapiens (human)
pyroptosisCaspase-3Homo sapiens (human)
leukocyte apoptotic processCaspase-3Homo sapiens (human)
cellular response to staurosporineCaspase-3Homo sapiens (human)
apoptotic signaling pathwayCaspase-3Homo sapiens (human)
intrinsic apoptotic signaling pathwayCaspase-3Homo sapiens (human)
execution phase of apoptosisCaspase-3Homo sapiens (human)
positive regulation of pyroptosisCaspase-3Homo sapiens (human)
positive regulation of amyloid-beta formationCaspase-3Homo sapiens (human)
epithelial cell apoptotic processCaspase-3Homo sapiens (human)
keratinocyte differentiationCaspase-3Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-3Homo sapiens (human)
neuron differentiationCaspase-3Homo sapiens (human)
proteolysisCaspase-4Homo sapiens (human)
inflammatory responseCaspase-4Homo sapiens (human)
protein autoprocessingCaspase-4Homo sapiens (human)
defense response to bacteriumCaspase-4Homo sapiens (human)
innate immune responseCaspase-4Homo sapiens (human)
regulation of inflammatory responseCaspase-4Homo sapiens (human)
positive regulation of inflammatory responseCaspase-4Homo sapiens (human)
defense response to Gram-positive bacteriumCaspase-4Homo sapiens (human)
protein maturationCaspase-4Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCaspase-4Homo sapiens (human)
pyroptosisCaspase-4Homo sapiens (human)
intrinsic apoptotic signaling pathwayCaspase-4Homo sapiens (human)
non-canonical inflammasome complex assemblyCaspase-4Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayCaspase-4Homo sapiens (human)
cellular response to amyloid-betaCaspase-4Homo sapiens (human)
positive regulation of interleukin-18-mediated signaling pathwayCaspase-4Homo sapiens (human)
apoptotic processCaspase-4Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-4Homo sapiens (human)
proteolysisCaspase-5Homo sapiens (human)
substantia nigra developmentCaspase-5Homo sapiens (human)
protein maturationCaspase-5Homo sapiens (human)
cellular response to mechanical stimulusCaspase-5Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-5Homo sapiens (human)
apoptotic processCaspase-5Homo sapiens (human)
positive regulation of inflammatory responseCaspase-5Homo sapiens (human)
response to hypoxiaCaspase-9Homo sapiens (human)
kidney developmentCaspase-9Homo sapiens (human)
response to ischemiaCaspase-9Homo sapiens (human)
apoptotic processCaspase-9Homo sapiens (human)
DNA damage responseCaspase-9Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageCaspase-9Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome cCaspase-9Homo sapiens (human)
protein processingCaspase-9Homo sapiens (human)
platelet formationCaspase-9Homo sapiens (human)
response to cobalt ionCaspase-9Homo sapiens (human)
response to estradiolCaspase-9Homo sapiens (human)
response to lipopolysaccharideCaspase-9Homo sapiens (human)
glial cell apoptotic processCaspase-9Homo sapiens (human)
cellular response to UVCaspase-9Homo sapiens (human)
signal transduction in response to DNA damageCaspase-9Homo sapiens (human)
positive regulation of apoptotic processCaspase-9Homo sapiens (human)
fibroblast apoptotic processCaspase-9Homo sapiens (human)
neuron apoptotic processCaspase-9Homo sapiens (human)
protein maturationCaspase-9Homo sapiens (human)
cellular response to dexamethasone stimulusCaspase-9Homo sapiens (human)
leukocyte apoptotic processCaspase-9Homo sapiens (human)
intrinsic apoptotic signaling pathwayCaspase-9Homo sapiens (human)
epithelial cell apoptotic processCaspase-9Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-9Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processCaspase-9Homo sapiens (human)
spliceosomal complex assemblySurvival motor neuron proteinHomo sapiens (human)
spliceosomal snRNP assemblySurvival motor neuron proteinHomo sapiens (human)
DNA-templated transcription terminationSurvival motor neuron proteinHomo sapiens (human)
nervous system developmentSurvival motor neuron proteinHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (56)

Processvia Protein(s)Taxonomy
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
magnesium ion bindingPyruvate kinase PKMHomo sapiens (human)
RNA bindingPyruvate kinase PKMHomo sapiens (human)
mRNA bindingPyruvate kinase PKMHomo sapiens (human)
protein tyrosine kinase activityPyruvate kinase PKMHomo sapiens (human)
pyruvate kinase activityPyruvate kinase PKMHomo sapiens (human)
protein bindingPyruvate kinase PKMHomo sapiens (human)
ATP bindingPyruvate kinase PKMHomo sapiens (human)
MHC class II protein complex bindingPyruvate kinase PKMHomo sapiens (human)
potassium ion bindingPyruvate kinase PKMHomo sapiens (human)
cadherin bindingPyruvate kinase PKMHomo sapiens (human)
endopeptidase activityCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-1Homo sapiens (human)
protein bindingCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCaspase-1Homo sapiens (human)
kinase bindingCaspase-1Homo sapiens (human)
cytokine bindingCaspase-1Homo sapiens (human)
identical protein bindingCaspase-1Homo sapiens (human)
CARD domain bindingCaspase-1Homo sapiens (human)
caspase bindingCaspase-1Homo sapiens (human)
protease bindingCaspase-3Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase inhibitor activityCaspase-3Homo sapiens (human)
death receptor bindingCaspase-3Homo sapiens (human)
protein bindingCaspase-3Homo sapiens (human)
peptidase activityCaspase-3Homo sapiens (human)
phospholipase A2 activator activityCaspase-3Homo sapiens (human)
protein-containing complex bindingCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic signaling pathwayCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-3Homo sapiens (human)
enzyme activator activityCaspase-3Homo sapiens (human)
lipopolysaccharide bindingCaspase-4Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-4Homo sapiens (human)
protein bindingCaspase-4Homo sapiens (human)
lipid bindingCaspase-4Homo sapiens (human)
CARD domain bindingCaspase-4Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-4Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-5Homo sapiens (human)
protein bindingCaspase-5Homo sapiens (human)
cysteine-type peptidase activityCaspase-5Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-5Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-9Homo sapiens (human)
protein bindingCaspase-9Homo sapiens (human)
enzyme activator activityCaspase-9Homo sapiens (human)
peptidase activityCaspase-9Homo sapiens (human)
SH3 domain bindingCaspase-9Homo sapiens (human)
protein kinase bindingCaspase-9Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-9Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic signaling pathwayCaspase-9Homo sapiens (human)
RNA bindingSurvival motor neuron proteinHomo sapiens (human)
protein bindingSurvival motor neuron proteinHomo sapiens (human)
identical protein bindingSurvival motor neuron proteinHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (73)

Processvia Protein(s)Taxonomy
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular regionPyruvate kinase PKMHomo sapiens (human)
nucleusPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
mitochondrionPyruvate kinase PKMHomo sapiens (human)
rough endoplasmic reticulumPyruvate kinase PKMHomo sapiens (human)
cytosolPyruvate kinase PKMHomo sapiens (human)
ciliumPyruvate kinase PKMHomo sapiens (human)
vesiclePyruvate kinase PKMHomo sapiens (human)
secretory granule lumenPyruvate kinase PKMHomo sapiens (human)
collagen-containing extracellular matrixPyruvate kinase PKMHomo sapiens (human)
extracellular exosomePyruvate kinase PKMHomo sapiens (human)
extracellular vesiclePyruvate kinase PKMHomo sapiens (human)
ficolin-1-rich granule lumenPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
nucleolusCaspase-1Homo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
microtubuleCaspase-1Homo sapiens (human)
plasma membraneCaspase-1Homo sapiens (human)
canonical inflammasome complexCaspase-1Homo sapiens (human)
NLRP1 inflammasome complexCaspase-1Homo sapiens (human)
NLRP3 inflammasome complexCaspase-1Homo sapiens (human)
AIM2 inflammasome complexCaspase-1Homo sapiens (human)
protein-containing complexCaspase-1Homo sapiens (human)
IPAF inflammasome complexCaspase-1Homo sapiens (human)
protease inhibitor complexCaspase-1Homo sapiens (human)
nucleusCaspase-3Homo sapiens (human)
cytoplasmCaspase-3Homo sapiens (human)
nucleusCaspase-3Homo sapiens (human)
nucleoplasmCaspase-3Homo sapiens (human)
cytosolCaspase-3Homo sapiens (human)
neuronal cell bodyCaspase-3Homo sapiens (human)
death-inducing signaling complexCaspase-3Homo sapiens (human)
cytosolCaspase-4Homo sapiens (human)
extracellular regionCaspase-4Homo sapiens (human)
mitochondrionCaspase-4Homo sapiens (human)
endoplasmic reticulumCaspase-4Homo sapiens (human)
endoplasmic reticulum membraneCaspase-4Homo sapiens (human)
cytosolCaspase-4Homo sapiens (human)
plasma membraneCaspase-4Homo sapiens (human)
protein-containing complexCaspase-4Homo sapiens (human)
non-canonical inflammasome complexCaspase-4Homo sapiens (human)
cytoplasmCaspase-4Homo sapiens (human)
NLRP1 inflammasome complexCaspase-4Homo sapiens (human)
cytosolCaspase-5Homo sapiens (human)
NLRP1 inflammasome complexCaspase-5Homo sapiens (human)
cytoplasmCaspase-5Homo sapiens (human)
mitochondrionCaspase-9Homo sapiens (human)
nucleusCaspase-9Homo sapiens (human)
cytosolCaspase-9Homo sapiens (human)
caspase complexCaspase-9Homo sapiens (human)
apoptosomeCaspase-9Homo sapiens (human)
protein-containing complexCaspase-9Homo sapiens (human)
cytosolCaspase-9Homo sapiens (human)
cytoplasmCaspase-9Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleusSurvival motor neuron proteinHomo sapiens (human)
nucleoplasmSurvival motor neuron proteinHomo sapiens (human)
cytoplasmSurvival motor neuron proteinHomo sapiens (human)
cytosolSurvival motor neuron proteinHomo sapiens (human)
Cajal bodySurvival motor neuron proteinHomo sapiens (human)
nuclear bodySurvival motor neuron proteinHomo sapiens (human)
Z discSurvival motor neuron proteinHomo sapiens (human)
axonSurvival motor neuron proteinHomo sapiens (human)
SMN complexSurvival motor neuron proteinHomo sapiens (human)
cytoplasmic ribonucleoprotein granuleSurvival motor neuron proteinHomo sapiens (human)
neuron projectionSurvival motor neuron proteinHomo sapiens (human)
perikaryonSurvival motor neuron proteinHomo sapiens (human)
Gemini of coiled bodiesSurvival motor neuron proteinHomo sapiens (human)
SMN-Sm protein complexSurvival motor neuron proteinHomo sapiens (human)
nucleusSurvival motor neuron proteinHomo sapiens (human)
Cajal bodySurvival motor neuron proteinHomo sapiens (human)
Gemini of coiled bodiesSurvival motor neuron proteinHomo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (48)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID1881891Inhibition of PKM2 (unknown origin) Gln329, Asp177, Lys207, Ser77, Hie78, Arg73, Ser362 residues2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
AID243647In vitro inhibitory activity against ovine cyclooxygenase-1 (COX-1) at 200 uM; Inactive2004Journal of medicinal chemistry, Sep-23, Volume: 47, Issue:20
Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID314380Displacement of [125I]TZDM from beta amyloid 42 fibril2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Isoindol-1,3-dione and isoindol-1-one derivatives with high binding affinity to beta-amyloid fibrils.
AID251770Inhibition of lipopolysaccharide-induced PGE-2 production at 10e-5 M2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
AID251807Inhibition of CXCL8-induced chemotaxis of human polymorphonuclear cells at 10e-8 M2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
AID616344Activation of SMN expressed in HEK293 cells assessed as concentration required to reach 50% of maximum luciferase signal by SMN2-promotor driven luciferase reporter gene assay2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Discovery, synthesis, and biological evaluation of novel SMN protein modulators.
AID384955Intrinsic aqueous solubility at pH 10 by shake-flask method2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID407366Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP high binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
AID384956Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID681927TP_TRANSPORTER: inhibition of E217betaG in the presence of Indoprofen at a concentration of 50uM in membrane vesicles from MRP4-expressing Sf9 cells2003Proceedings of the National Academy of Sciences of the United States of America, Aug-05, Volume: 100, Issue:16
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID407369Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP low binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
AID297159Inhibition of CXCL1-induced cell migration human PMN cells at 0.1 uM chemotaxis assay2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
AID297157Inhibition of CXCL8-induced cell migration in human PMN cells at 0.01 uM by chemotaxis assay2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
AID1802657Caspase Catalytic Activity Assay from Article 10.1016/j.chembiol.2017.02.003: \\Non-steroidal Anti-inflammatory Drugs Are Caspase Inhibitors.\\2017Cell chemical biology, Mar-16, Volume: 24, Issue:3
Non-steroidal Anti-inflammatory Drugs Are Caspase Inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (156)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990108 (69.23)18.7374
1990's5 (3.21)18.2507
2000's21 (13.46)29.6817
2010's16 (10.26)24.3611
2020's6 (3.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.40 (24.57)
Research Supply Index5.42 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials60 (36.14%)5.53%
Reviews3 (1.81%)6.00%
Case Studies3 (1.81%)4.05%
Observational0 (0.00%)0.25%
Other100 (60.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]